Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Change in Cash (2016 - 2025)

Historic Change in Cash for Ani Pharmaceuticals (ANIP) over the last 17 years, with Q3 2025 value amounting to $44.8 million.

  • Ani Pharmaceuticals' Change in Cash rose 14712.54% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $117.6 million, marking a year-over-year increase of 34474.94%. This contributed to the annual value of -$76.2 million for FY2024, which is 14540.38% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Change in Cash is $44.8 million, which was up 14712.54% from $68.0 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Change in Cash ranged from a high of $94.0 million in Q2 2023 and a low of -$95.1 million during Q3 2024
  • Its 5-year average for Change in Cash is $13.1 million, with a median of $7.5 million in 2024.
  • In the last 5 years, Ani Pharmaceuticals' Change in Cash soared by 94740.93% in 2021 and then plummeted by 156769.42% in 2022.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Change in Cash stood at $85.0 million in 2021, then tumbled by 109.47% to -$8.0 million in 2022, then skyrocketed by 448.36% to $28.0 million in 2023, then plummeted by 100.44% to -$123000.0 in 2024, then surged by 36533.33% to $44.8 million in 2025.
  • Its last three reported values are $44.8 million in Q3 2025, $68.0 million for Q2 2025, and $4.9 million during Q1 2025.